Ani Pharmaceuticals (ANIP) Cash & Current Investments (2010 - 2026)

Ani Pharmaceuticals has reported Cash & Current Investments for 17 years, with the latest figure at $311.2 million in Q1 2026.

• Quarterly Cash & Current Investments rose 107.7% year-over-year to $311.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311.2 million (up 107.7% YoY) and the FY2025 annual result came in at $285.6 million, up 97.12% from the prior year.
• Cash & Current Investments grew to $311.2 million in Q1 2026 per ANIP's latest filing, from $285.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $311.2 million in Q1 2026 and troughed at $53.2 million in Q4 2022.
• A 5-year average of $170.2 million and a median of $161.7 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments tumbled 49.45% in 2022, then surged 315.38% in 2023.
• Over 5 years, Cash & Current Investments stood at $53.2 million in 2022, then jumped by 315.38% to $221.1 million in 2023, then tumbled by 34.47% to $144.9 million in 2024, then jumped by 97.12% to $285.6 million in 2025, then rose by 8.96% to $311.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $311.2 million, $285.6 million, and $262.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.